Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cactus extract could zap cancer pain in new trial

NCT ID NCT00804154

Recruiting now Symptom relief Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 6 times

Summary

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial involves 45 adults with advanced cancer and will check safety and pain relief over several months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
resiniferatoxin (RTX), a chemical from a cactus-like plant similar to capsaicin
What this could lead to
If it works, this could provide a new way to relieve severe cancer pain that doesn't respond to standard treatments.
What could go wrong
This is an early Phase 1 study with only 45 people, so safety and effectiveness are not yet proven. The drug destroys pain nerves, which may cause lasting numbness or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Cancer Pain Pain, Intractable

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACTABLE PAIN PALLIATIVE CARE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.